{"name":"Altor BioScience","slug":"altor-bioscience","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2024-01-01","label":"Anktiva first approved","drug":"Anktiva","drugSlug":"inbakicept","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-03-01","label":"Anktiva PHASE2,PHASE3 readout","drug":"Anktiva","drugSlug":"inbakicept","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-12-31","label":"ANKTIVA Phase 3 readout (Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS))","drug":"ANKTIVA","drugSlug":"nogapendekin-alfa-inbakicept-pmln","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Anktiva","genericName":"INBAKICEPT","slug":"inbakicept","indication":"BCG-unresponsive NMIBC with CIS","status":"marketed"},{"name":"ALT-836 in combination with gemcitabine","genericName":"ALT-836 in combination with gemcitabine","slug":"alt-836-in-combination-with-gemcitabine","indication":"Other","status":"phase_1"},{"name":"ALT-836","genericName":"ALT-836","slug":"alt-836","indication":"Other","status":"phase_2"},{"name":"ANKTIVA","genericName":"nogapendekin alfa inbakicept-pmln","slug":"nogapendekin-alfa-inbakicept-pmln","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Anktiva","genericName":"INBAKICEPT","slug":"inbakicept","phase":"marketed","mechanism":"Anktiva works by targeting a specific target to treat BCG-unresponsive nonmuscle invasive bladder cancer.","indications":["BCG-unresponsive NMIBC with CIS"],"catalyst":""},{"name":"ALT-836 in combination with gemcitabine","genericName":"ALT-836 in combination with gemcitabine","slug":"alt-836-in-combination-with-gemcitabine","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ALT-836","genericName":"ALT-836","slug":"alt-836","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ANKTIVA","genericName":"nogapendekin alfa inbakicept-pmln","slug":"nogapendekin-alfa-inbakicept-pmln","phase":"marketed","mechanism":"","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNTkMzU2ZIQ0hnV0xGam1hRE1Ea3ZMVHhPc1lVMUVlZHJHeWJzX2h0V2dRYXpLbXdLSlNSSmpPZ3pJYkJCdm1VUW0xeGFzR3RxSklTZ0U0bVFPejB3R3ByMTBOXzdFeU0zNW9xQlFxbE9QeUJNa3Vab0QzRFpzMnJuT2huYVZRYjNYVU5hRHFSbw?oc=5","date":"2026-01-15","type":"pipeline","source":"Medical Marketing and Media","summary":"OPDP sends second Untitled Letter to Altor BioScience after prior concerns went unaddressed - Medical Marketing and Media","headline":"OPDP sends second Untitled Letter to Altor BioScience after prior concerns went unaddressed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxQT195Um84VEw5TDFnZ0x5N0VydUJ0aDNTVGF1SDVWdjh0bEFwbEtyZzM4R2ZEbENDdTVwQzJSV0ZrUU9JSlVZbTZ5TXlYd3NyYmpXT3pVMzdEUHRuTi1lYURucmpkR2M4bzJTeTFNU05iM3dIX0JNNzdoT1otUWVoT3VZamZrTzA5bmYxaUxmTEMxZVpuWm5aRFlVdmZWeXRxU2lWclBRLXg0eEZndGl6VkxBUGRYWjFHdHp0bU9jdnQ1SmpfLXlOd3dPTkhSMTJPRHdDZlpfMjdHQjNyR21Zd2pnU21aQTNOam1SZUw5ZkNyb19xOUMyc0pxRnl4Z2hnRHdLc19CTkdQSy1EYTdDTFRuYkZYRHE0S2tFYm1TMVI?oc=5","date":"2025-10-14","type":"trial","source":"GlobeNewswire","summary":"Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma - GlobeNewswire","headline":"Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQcGhObzRGVFNvdEo4T2hPa2laVTV5WlhxTTVpTzJjWGhEZlhCRDRNTWF5Q0JPc2t2eHV4MUY3cWpmb1lROTJKRUJnbzZZTUhuemlBZVRaTnZBOWJxY1BPcjBpN1BZdUJNakd0UW04QnU2TlJ2NTZKVEViLWxQMi1MN2xTTQ?oc=5","date":"2025-09-26","type":"pipeline","source":"Fortune Business Insights","summary":"Bladder Cancer Vaccines Market Size, Share | Forecast [2034] - Fortune Business Insights","headline":"Bladder Cancer Vaccines Market Size, Share | Forecast [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOOGdIUmV0anRSZTI1NFNoTHk0TThPOGtxdjMyYnhXR3F2NndDaV9NQzJiNWNSZVZpN2wyTDJBMWkwTm03UWZJbUs2V1hob0xrc3p1ajg2bUpOamxacEJxcm5jekJkN2dzOE1zcjZRdXdMR3IzTXpiVzRCN3EyQ3libkhkQQ?oc=5","date":"2025-03-31","type":"trial","source":"Oncology Pipeline","summary":"Aura bids to join the bladder cancer crowd | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Aura bids to join the bladder cancer crowd | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1tbHA0bE5WMzd5Z0NBZnpGbkE4ZkxwWE5uZmdQOURuLVc1V1R5bElyLXZYcUdObEhZQ3NIdXFOVHVILTV6cEdmV3BRSDVFWmZTVFZCQ25udi1JbnpXYkxHTFZBOGNnc0VoZkEyZWFfZEZqZnM0c3FQa2lJZ0w?oc=5","date":"2024-04-23","type":"trial","source":"Oncology Pipeline","summary":"Anktiva’s tortuous journey ends | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Anktiva’s tortuous journey ends | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOaDE2WmplRzE1NEljQURsaVRPc2hjeWYta0xWelByNEpVTHJnNU5xSzJZRFl4dnlSREN4S2dsTElncm5xZFZ6aXpiWkh2RkZ1NjRIX0tSQ0I0ZWtCSk8wZ05jMl9kSFFpeE94OFQxUUVUREQ4X1BWMkhUYURwaHlXZHpocktBdUlmTXF4R21QS192cXRZdWNhWUNnU0RrX3J4RWc?oc=5","date":"2024-04-23","type":"regulatory","source":"Los Angeles Times","summary":"FDA approves bladder cancer treatment by Culver City company - Los Angeles Times","headline":"FDA approves bladder cancer treatment by Culver City company","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPQnJzck5HQnI4SWhDeUxsYkhSdkFSWG9oN3M2YVdvM0tMRlVRbnVNR0I3X1JJY1YxSDNkeXdSVTdITU85aVlHRVMtVDdvOXZtcHM5VzNIMGZuT3ZrRXlXMUhzdUF0Y2V0S3pCSGIxWV81UDhXMHlkQ3E0ZDlPUVBTRnlibVBBZTFuSGpV?oc=5","date":"2023-03-10","type":"pipeline","source":"drugdiscoverytrends.com","summary":"The top 100 cell and gene therapy companies to watch in 2023 - drugdiscoverytrends.com","headline":"The top 100 cell and gene therapy companies to watch in 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQR1lXR25JREJaVk5GSE5JYzlVUDNsRVQ0X3JKdk9nbWVySXgyLWtZWnA3Z05uQmtKTXJSZXQwOFdqd00yNUxSSHlxdkVvZnVRZEVUV0RyTU5UbWdVcDlVdEhsUjFfbjVNZWE4QUtEc3ZRcDN4djVEbEpLd3llUDlucGJyOWZRVlMycFBNOTdkeEVWOFhnZkE?oc=5","date":"2018-01-09","type":"pipeline","source":"Politico","summary":"Cher escalates legal feud with Soon-Shiong - Politico","headline":"Cher escalates legal feud with Soon-Shiong","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNbXl4ZWtjd0IyRFNoblpPdWRLaks3eWhWS1RuMnR6RkVnR3lCRnd2a0dMenFMUGNzOTNheHE5NHI3S3JTOXFURUhhbk5hTDA5Q3RUZE5PeF9kZWI1c2R5NENJNG9wOHhKSzhLS3pCMUt5U1N1NHpkUHA0cnRaUDF0dGZKWG85T3A0RE5QVHh6UFo1MS1k?oc=5","date":"2017-10-02","type":"pipeline","source":"WSJ","summary":"Cher Sues Billionaire Entrepreneur Over Stock Sale - WSJ","headline":"Cher Sues Billionaire Entrepreneur Over Stock Sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPTkEwc0RwU0dWNVRPRk5FSjFSVWd3QVhLWEczdmtWdDVKQ3JpeUpOc2JXWTMxVXk3cG11ckx3SFRFaEZLS2IxY1p0MWlBT2JDazVJQ3BhOEQ3ckF6Q0RhTktKS1FfOVVyaDI4c2dXZFROZWo3aTJTV3E4S0gyMzlhMzhEQmZaZ1RrQ1JyRzhyMncwLXNlS2gwenQxdVdtQW1pR0liUG42UzdiQQ?oc=5","date":"2017-06-27","type":"deal","source":"Fierce Biotech","summary":"Despite 'looting' claims, Soon-Shiong’s NantCell to buy Altor - Fierce Biotech","headline":"Despite 'looting' claims, Soon-Shiong’s NantCell to buy Altor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOUk5pcjZHOVJPcy1lUzJhNVRrWXF6anQ3SkZiT3hiM3p2bi1lNnNWaXhRdDFYREhJNTJMbUxiOHFmM280aldSRXQxUG80LU12emgzcmg4b29vNGJremN4TlZqM0JLZFRHTUQyRWNUMmVSeGYzNXFCMXlHejlxQWFoNnl0Snc2RU1QM2lBbXRjYTR3Q3FlXzVZdXU2akg5NE5kSFRWNE5HbU1FWmJfc0x6VFVibFc0dEE?oc=5","date":"2016-10-04","type":"pipeline","source":"Fierce Biotech","summary":"I/O pair Altor BioScience and NantKwest team up for experimental combo studies - Fierce Biotech","headline":"I/O pair Altor BioScience and NantKwest team up for experimental combo studies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTFBKc1BqMVUxMnlZV29MdU9nZHFVblZpbTZPWFNhZWwwUWRSMkcxaHh5Q1NvUVpuRk5qd2I1UGhwV0VCSHZLSFdLVVFrNnI1dkNoQzdGdTM4QQ?oc=5","date":"2013-11-01","type":"pipeline","source":"Nature","summary":"Monoclonal T-cell receptor drugs pique pharma's interest - Nature","headline":"Monoclonal T-cell receptor drugs pique pharma's interest","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":2,"phase_1":1,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}